Dr. Michael R. Hayden

Dr. Hayden is a Killam Professor at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only 4 such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also a Senior Scientist at the Centre for Molecular Medicine and Therapeutics, UBC.

Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva from 2012-2017. During this time, approximately 35 new products were approved in major markets with many for diseases of the CNS and led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD.

Dr. Hayden was named one of the 50 Canadians born in the 20th century who have changed the world. Dr. Hayden is the co-founder of five biotechnology companies including: Prilenia, NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp, and 89bio. He currently sits on different public and private boards of biotechnologies companies.

Author of approximately 900 peer-reviewed publications and invited submissions, Dr. Hayden has focused his research primarily on translational medicine, including genetics, lipoprotein disorders, Huntington disease, predictive, personalized medicine and drug development. Dr. Hayden and his research group have identified 10 disease-causing genes which includes the identification of the major gene underlying high-density lipoprotein (HDL) in humans. Dr. Hayden also identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency and developed gene therapy approaches to treat this condition resulting in the first approved gene therapy product (Glybera) in a major market. Dr. Hayden has been the most cited author in the world on ABCA1, and Huntington Disease since 2006.

Dr. Hayden is the recipient of numerous prestigious honours and awards. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2022), ranked #22 Top Medicine Scientists in Canada (Research.com), awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka Medical Center (2020), and inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice’s “100 of the Most Inspiring People” (2015); awarded an Honorary Doctorate of Science by the University of Alberta (2009) and the University of Gottingen (2014); the Luminary award by the Personalized Medicine World Conference (2014); the Diamond Jubilee Medal (2012), on behalf of HRH Queen Elisabeth II, the Killam Prize by the Canada Council of the Arts (2011), in recognition of his outstanding career achievements; and the Canada Gairdner Wightman award (2011). Dr. Hayden has also been awarded the Order of Canada (2011), and the Order of British Columbia (2010). He was named Canada’s Health Researcher of the Year by CIHR in 2008, and he received the Prix Galien in 2007.

Dr. Hayden is committed to empowering others. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor.

One response to “Dr. Michael R. Hayden”

  1. Udo Hartmann

    Good evening Dr. Hayden,

    I read the article in the NYT. I’m sure you searched this website: https://www.ebay.de/sch/i.html?_from=R40&_trksid=p4432023.m570.l1311&_nkw=judaica+silber&_sacat=0.
    If I can be of any help let me know.


    Udo Hartmann
    German attorney

Leave a Reply